By Colin Kellaher

Harpoon Therapeutics Inc. signed a supply agreement with Roche Holding AG under which Harpoon plans to add Roche's cancer drug Tecentriq to its HPN328 development program, Harpoon said Monday.

The clinical-stage immunotherapy company plans to evaluate HPN328 in combination with Tecentriq in patients with small cell lung cancer, it said.

The South San Francisco, Calif., would sponsor of the anticipated clinical trials, while Roche would supply Tecentriq, Harpoon said.

Harpoon shares, which closed Friday at $2.25, rose 6.7%, to $2.40, in premarket trading Monday.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

May 02, 2022 09:34 ET (13:34 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Roche (QX) Charts.